Review





Similar Products

94
Shanghai Korain Biotech Co Ltd human e selectin sele elisa kit
Human E Selectin Sele Elisa Kit, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/Human+E-Selectin/10__1186_slash_s12882___026___05349___3-52-5-11
Average 94 stars, based on 1 article reviews
human e selectin sele elisa kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Bio X Cell anti cd62e
a Construction of the exosome-relocalizing nanosystem, DNPC AC , designed to enhance myocardial exposure to endogenous endothelial exosomes after ischemic injury. The nanosystem integrates dendritic mesoporous silica nanoparticles (DMSN) carriers, the myocardium-targeting peptide (CTP), and an <t>anti-CD62E</t> antibody to selectively bind injury-evoked endothelial exosomes. b Mechanistic illustration of DNPC AC -mediated endothelial exosome relocalization in the ischemic myocardium. Ischemic injury induces endothelial activation and exosome release into the circulation. DNPC AC captures these injury-evoked endothelial exosomes (i), delivers them to the ischemic myocardium (ii), and releases them locally in response to the acidic microenvironment (iii), thereby enhancing angiocrine signal utilization and improving cardiomyocyte survival and inhibiting subsequent significant myocardial injury and remodeling.
Anti Cd62e, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/InVivoMAb+anti-mouse+E-selectin/pmc13752274-391-6-10
Average 94 stars, based on 1 article reviews
anti cd62e - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
RayBiotech inc human e selectin elisa kit
a Construction of the exosome-relocalizing nanosystem, DNPC AC , designed to enhance myocardial exposure to endogenous endothelial exosomes after ischemic injury. The nanosystem integrates dendritic mesoporous silica nanoparticles (DMSN) carriers, the myocardium-targeting peptide (CTP), and an <t>anti-CD62E</t> antibody to selectively bind injury-evoked endothelial exosomes. b Mechanistic illustration of DNPC AC -mediated endothelial exosome relocalization in the ischemic myocardium. Ischemic injury induces endothelial activation and exosome release into the circulation. DNPC AC captures these injury-evoked endothelial exosomes (i), delivers them to the ischemic myocardium (ii), and releases them locally in response to the acidic microenvironment (iii), thereby enhancing angiocrine signal utilization and improving cardiomyocyte survival and inhibiting subsequent significant myocardial injury and remodeling.
Human E Selectin Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/Human+E-Selectin+ELISA/pm42790593-114-23-27
Average 94 stars, based on 1 article reviews
human e selectin elisa kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
Proteintech endothelial cell apoptosis
a Construction of the exosome-relocalizing nanosystem, DNPC AC , designed to enhance myocardial exposure to endogenous endothelial exosomes after ischemic injury. The nanosystem integrates dendritic mesoporous silica nanoparticles (DMSN) carriers, the myocardium-targeting peptide (CTP), and an <t>anti-CD62E</t> antibody to selectively bind injury-evoked endothelial exosomes. b Mechanistic illustration of DNPC AC -mediated endothelial exosome relocalization in the ischemic myocardium. Ischemic injury induces endothelial activation and exosome release into the circulation. DNPC AC captures these injury-evoked endothelial exosomes (i), delivers them to the ischemic myocardium (ii), and releases them locally in response to the acidic microenvironment (iii), thereby enhancing angiocrine signal utilization and improving cardiomyocyte survival and inhibiting subsequent significant myocardial injury and remodeling.
Endothelial Cell Apoptosis, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/Mouse+E-selectin%2FCD62E+ELISA+Kit/pm41903544-691-0-17
Average 92 stars, based on 1 article reviews
endothelial cell apoptosis - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

86
Biocell Technology e selectin primary antibody
a Construction of the exosome-relocalizing nanosystem, DNPC AC , designed to enhance myocardial exposure to endogenous endothelial exosomes after ischemic injury. The nanosystem integrates dendritic mesoporous silica nanoparticles (DMSN) carriers, the myocardium-targeting peptide (CTP), and an <t>anti-CD62E</t> antibody to selectively bind injury-evoked endothelial exosomes. b Mechanistic illustration of DNPC AC -mediated endothelial exosome relocalization in the ischemic myocardium. Ischemic injury induces endothelial activation and exosome release into the circulation. DNPC AC captures these injury-evoked endothelial exosomes (i), delivers them to the ischemic myocardium (ii), and releases them locally in response to the acidic microenvironment (iii), thereby enhancing angiocrine signal utilization and improving cardiomyocyte survival and inhibiting subsequent significant myocardial injury and remodeling.
E Selectin Primary Antibody, supplied by Biocell Technology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/antibody+e+primary+selectin/pm42260622-280-6-11
Average 86 stars, based on 1 article reviews
e selectin primary antibody - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

93
R&D Systems anti human e selectin ab
(A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
Anti Human E Selectin Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/Human+E-Selectin%2FCD62E+Antibody/bio_rxiv__64898__2026__04__08__717301-188-12-15
Average 93 stars, based on 1 article reviews
anti human e selectin ab - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

86
Pfizer Inc human e selectin
(A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
Human E Selectin, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/e+human+selectin/us12577308-2310-3-7
Average 86 stars, based on 1 article reviews
human e selectin - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

94
R&D Systems e selectin
(A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
E Selectin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/Recombinant+Human+E-Selectin%2FCD62E+Protein%2C+CF/us12577308-1819-20-21
Average 94 stars, based on 1 article reviews
e selectin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Sino Biological recombinant human p selectin
(A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
Recombinant Human P Selectin, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/Human+E-Selectin+SELE+Protein/us12577308-2320-11-16
Average 94 stars, based on 1 article reviews
recombinant human p selectin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Sino Biological human e selectin
(A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.
Human E Selectin, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e+selectin/Human+SELP+%2F+selectin+P+%2F+P-selectin+Protein/us12577308-2105-18-20
Average 94 stars, based on 1 article reviews
human e selectin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


a Construction of the exosome-relocalizing nanosystem, DNPC AC , designed to enhance myocardial exposure to endogenous endothelial exosomes after ischemic injury. The nanosystem integrates dendritic mesoporous silica nanoparticles (DMSN) carriers, the myocardium-targeting peptide (CTP), and an anti-CD62E antibody to selectively bind injury-evoked endothelial exosomes. b Mechanistic illustration of DNPC AC -mediated endothelial exosome relocalization in the ischemic myocardium. Ischemic injury induces endothelial activation and exosome release into the circulation. DNPC AC captures these injury-evoked endothelial exosomes (i), delivers them to the ischemic myocardium (ii), and releases them locally in response to the acidic microenvironment (iii), thereby enhancing angiocrine signal utilization and improving cardiomyocyte survival and inhibiting subsequent significant myocardial injury and remodeling.

Journal: Nature Communications

Article Title: A nanosystem manipulates angiocrine signaling for cardioprotection in male mice by relocalizing endothelial exosomes

doi: 10.1038/s41467-026-78706-3

Figure Lengend Snippet: a Construction of the exosome-relocalizing nanosystem, DNPC AC , designed to enhance myocardial exposure to endogenous endothelial exosomes after ischemic injury. The nanosystem integrates dendritic mesoporous silica nanoparticles (DMSN) carriers, the myocardium-targeting peptide (CTP), and an anti-CD62E antibody to selectively bind injury-evoked endothelial exosomes. b Mechanistic illustration of DNPC AC -mediated endothelial exosome relocalization in the ischemic myocardium. Ischemic injury induces endothelial activation and exosome release into the circulation. DNPC AC captures these injury-evoked endothelial exosomes (i), delivers them to the ischemic myocardium (ii), and releases them locally in response to the acidic microenvironment (iii), thereby enhancing angiocrine signal utilization and improving cardiomyocyte survival and inhibiting subsequent significant myocardial injury and remodeling.

Article Snippet: DNPC AC was constructed by conjugating anti-CD62E (InVivoMAb anti-mouse E-selectin, BioXcell; BE0294, AB_2687816) and CTP (CSTSMLKAC, Supplementary Fig. S1-Fig. S2) on DNPC.

Techniques: Exosomes, Activation Assay

a Schematic illustration of the multi-step synthesis route for DMSN modification, including surface vinylation, carboxylation, hydrazide functionalization, and PEG-dialdehyde conjugation to yield DNPC nanoparticles. b TEM images of DNPC nanoparticles, inset shows the corresponding SAED pattern. Scale bar, 100 nm. c HAADF scanning transmission electron microscopy image and elemental mapping confirming homogeneous distribution of Si, O, N, C across DNPC. Scale bar, 100 nm. d DLS analysis of DNPC showing an average hydrodynamic diameter of 187.1 ± 4.17 nm. e XRD patterns of DMSN and DNPC. f N 2 adsorption–desorption isotherms and pore size distribution demonstrating a mesoporous network with an average pore diameter of 34.5 nm. g FTIR spectra validating stepwise surface modification of DMSN through functional group engineering. h Zeta potential measurements illustrating surface charge transitions after each modification. i , Schematic representation of DNPC AC formation through Schiff-base coupling with FITC-labeled cardiac-targeting peptide (CTP) and anti-CD62E antibody. j TGA curves of DNPC and DNPC AC showing organic ligand and protein loading ratios (~30%). k Fluorescence microscopy images of DNPC AC and DMSN AC (FITC and TR double-labeled) confirming successful dual conjugation. Scale bars, 200 nm. l Quantification of antibody/polypeptide adsorption efficiency between DNPC AC and DMSN AC . m TEM image showing direct interaction and surface adsorption between DNPC AC and exosomes. Scale bars, 100 nm and 50 nm (large). n Confocal fluorescence images showing colocalization of FITC-labeled DNPC AC (green) with PKH67-labeled exosomes (red). Scale bars, 1 μm. o Flow cytometry analysis showing enhanced exosome-binding efficiency of DNPC AC compared to DNPC. p , Statistical comparison of exosome capture efficiency between DNPC AC and DNPC. The data in ( h , l, p ) are shown as mean ± s.d., n = 3 independent samples ( h ), n = 5 independent samples ( l, p ). The experiments in ( b, c, m, n ) were independently repeated three times with similar results. Statistical analysis was performed using a two-tailed unpaired Student’s t -test ( l, p ). NS, not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: A nanosystem manipulates angiocrine signaling for cardioprotection in male mice by relocalizing endothelial exosomes

doi: 10.1038/s41467-026-78706-3

Figure Lengend Snippet: a Schematic illustration of the multi-step synthesis route for DMSN modification, including surface vinylation, carboxylation, hydrazide functionalization, and PEG-dialdehyde conjugation to yield DNPC nanoparticles. b TEM images of DNPC nanoparticles, inset shows the corresponding SAED pattern. Scale bar, 100 nm. c HAADF scanning transmission electron microscopy image and elemental mapping confirming homogeneous distribution of Si, O, N, C across DNPC. Scale bar, 100 nm. d DLS analysis of DNPC showing an average hydrodynamic diameter of 187.1 ± 4.17 nm. e XRD patterns of DMSN and DNPC. f N 2 adsorption–desorption isotherms and pore size distribution demonstrating a mesoporous network with an average pore diameter of 34.5 nm. g FTIR spectra validating stepwise surface modification of DMSN through functional group engineering. h Zeta potential measurements illustrating surface charge transitions after each modification. i , Schematic representation of DNPC AC formation through Schiff-base coupling with FITC-labeled cardiac-targeting peptide (CTP) and anti-CD62E antibody. j TGA curves of DNPC and DNPC AC showing organic ligand and protein loading ratios (~30%). k Fluorescence microscopy images of DNPC AC and DMSN AC (FITC and TR double-labeled) confirming successful dual conjugation. Scale bars, 200 nm. l Quantification of antibody/polypeptide adsorption efficiency between DNPC AC and DMSN AC . m TEM image showing direct interaction and surface adsorption between DNPC AC and exosomes. Scale bars, 100 nm and 50 nm (large). n Confocal fluorescence images showing colocalization of FITC-labeled DNPC AC (green) with PKH67-labeled exosomes (red). Scale bars, 1 μm. o Flow cytometry analysis showing enhanced exosome-binding efficiency of DNPC AC compared to DNPC. p , Statistical comparison of exosome capture efficiency between DNPC AC and DNPC. The data in ( h , l, p ) are shown as mean ± s.d., n = 3 independent samples ( h ), n = 5 independent samples ( l, p ). The experiments in ( b, c, m, n ) were independently repeated three times with similar results. Statistical analysis was performed using a two-tailed unpaired Student’s t -test ( l, p ). NS, not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Source data are provided as a Source Data file.

Article Snippet: DNPC AC was constructed by conjugating anti-CD62E (InVivoMAb anti-mouse E-selectin, BioXcell; BE0294, AB_2687816) and CTP (CSTSMLKAC, Supplementary Fig. S1-Fig. S2) on DNPC.

Techniques: Modification, Conjugation Assay, Scanning Transmission Electron Microscopy, Elemental Analysis, Analysis, Adsorption, Pore Size, Functional Assay, Zeta Potential Analyzer, Labeling, Fluorescence, Microscopy, Exosomes, Confocal, Flow Cytometry, Binding Assay, Comparison, Two Tailed Test, Binding Capacity

(A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human E-selectin antibody (BBA16; αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Journal: bioRxiv

Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

doi: 10.64898/2026.04.08.717301

Figure Lengend Snippet: (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human E-selectin antibody (BBA16; αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Alternatively, HUVECs were incubated with mouse IgG (Leinco Technologies, Inc., I-536) or anti-human E-selectin Ab (R&D Systems, BBA16) at 25 μg/mL for 30 minutes at 37°C.

Techniques: Cell Adhesion Assay, Staining, Control, Knock-Out, Negative Control, Two Tailed Test

(A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Journal: bioRxiv

Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

doi: 10.64898/2026.04.08.717301

Figure Lengend Snippet: (A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Alternatively, HUVECs were incubated with mouse IgG (Leinco Technologies, Inc., I-536) or anti-human E-selectin Ab (R&D Systems, BBA16) at 25 μg/mL for 30 minutes at 37°C.

Techniques: Injection, Isolation, Control, Two Tailed Test